(S)-Ceralasertib (Synonyms: (S)-AZD6738) |
Catalog No.GC34999 |
(S)-Ceralasertib((S)-AZD6738)은 특허 WO2011154737A1, 화합물 II에서 추출되며 2.578 nM의 IC50을 나타냅니다.(S)-Ceralasertib은 우수한 전임상 및 PK를 가진 강력하고 선택적인 설폭시민 모르폴리노피리미딘 ATR 억제제입니다. ) 특성.(S)-Ceralasertib은 수용성을 개선하고 CYP3A4 시간 의존적 억제를 제거하기 위해 개발되었습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1352226-87-9
Sample solution is provided at 25 µL, 10mM.
(S)-Ceralasertib is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM[1].(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.(S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition[2].
[1]. By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215. [2]. Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *